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Cigarette smoking is a major risk factor for chronic
obstructive pulmonary disease and is presumed to
be central to the altered responsiveness to recur-
rent infection in these patients. We examined the ef-
fects of smoke priming underlying the exacerbated
response to viral infection in mice. Lack of
interleukin-33 (IL-33) signaling conferred complete
protection during exacerbation and prevented
enhanced inflammation and exaggerated weight
loss. Mechanistically, smoke was required to upre-
gulate epithelial-derived IL-33 and simultaneously
alter the distribution of the IL-33 receptor ST2. Spe-
cifically, smoke decreased ST2 expression on group
2 innate lymphoid cells (ILC2s) while elevating ST2
expression on macrophages and natural killer (NK)
cells, thus altering IL-33 responsiveness within the
lung. Consequently, upon infection and release,
increased local IL-33 significantly amplified type I
proinflammatory responses via synergistic modula-
tion of macrophage and NK cell function. Therefore,
in COPD, smoke alters the lung microenvironment
to facilitate an alternative IL-33-dependent exagger-
ated proinflammatory response to infection, exacer-
bating disease.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a lung disor-
der defined by irreversible and progressive airflow obstruction.
Acute exacerbations in COPD are associated with viral and/or
bacterial infections (Sethi and Murphy, 2008; Mohan et al.,
2010). Frequent exacerbations accelerate disease progression,
impair quality of life, increase the risk of hospitalization, and
are a major cause of mortality in these patients (Donaldson
et al., 2002). Further, they are characteristically more severe,566 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.prolonged, and associated with enhanced inflammatory re-
sponses (MacDonald et al., 2013; Mallia et al., 2011).
Cigarette smoke exposure has a major impact on respiratory
health and is considered to be the primary causative agent in
COPD. How smoking alters the immune system and leads to a
chronic and poorly controlled inflammatory disease is the sub-
ject of intense investigation. Infection of mice on a background
of smoke results in exaggerated inflammation and delayed reso-
lution (Bauer et al., 2013), and several studies have implicated a
role for the interleukin-1 (IL-1) family members IL-1a and IL-18 in
COPD and corresponding mouse models (Botelho et al., 2011a;
Kang et al., 2008).
IL-33 is a largely stromal-derived cytokine belonging to the
IL-1 family (Onda et al., 1999; Baekkevold et al., 2003; Schmitz
et al., 2005; Moussion et al., 2008) and is primarily associated
with T helper 2 (Th2) cell immunity via induction of IL-13, from
type 2 innate lymphoid cells (ILCs) and Th2 cells (Neill et al.,
2010; Xu et al., 1998; Lo¨hning et al., 1998; Coyle et al., 1999).
The IL-33/ST2 axis has been implicated in a number of inflamma-
tory settings including asthma, influenza-associated airway hy-
peractivity (AHR), and allergic rhinitis (Bartemes et al., 2012;
Palmer and Gabay, 2011; Chang et al., 2011); however, more
recently a role for this pathway has been shown in non Th2-like
diseases, such as rheumatoid arthritis, inflammatory bowel dis-
ease, and pain (Palmer and Gabay, 2011; Hams and Fallon,
2012; Verri et al., 2008). Although not defined, release of this
cytokine is thought to be mainly triggered via cell necrosis/dam-
age (Kouzaki et al., 2011; Cayrol and Girard, 2009). Notably,
airway damage is a hallmark of COPD and is associated with
prolonged exposure to cigarette smoke and microbial patho-
gens (Sethi and Murphy, 2008; Tuder and Petrache, 2012). A
recent study showed that IL-33 is elevated in severe COPD
and is associated with an IL-13- and mucin gene-like signature
(Byers et al., 2013); however, whether IL-33 plays a role in exac-
erbations is unknown.
In this study, we have used a combination of cigarette
smoke and infection to model exacerbations of COPD in
mice and shown that on the background of smoke expo-
sure, exaggerated inflammation to infection is completely
attenuated in the absence of IL-33 signaling. Mechanistically,
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Figure 1. IL-33 Is a Critical Mediator of Smoke-Induced Exacerbations of Influenza A Infection
Il1rl1/, Il33/, and BALB/c mice were exposed to cigarette smoke for 4 days, followed by virus infection on day 5.
(A) Body weights were recorded throughout the experiment.
(B) Leukocyte subsets in lung tissue were assessed by flow cytometry on day 11.
(C) Cytokine concentrations were determined on day 7 in BAL supernatant by ELISA or MSD analysis.
In this study, mice in which IL-33 signaling was blocked via ST2-Fc throughout the duration of virus infection (days 5–11) were also included.
(D) On day 11, inflammation was quantified in BAL by lavage of the airways and differential counting of cytospins.
(E) Viral load was measured on day 11 by quantification of viral M protein in whole lung by Taqman.
Data are expressed asmean ± SEM, n = 8–16mice per group from two separate experiments, *p < 0.05, **p < 0.01, ***p < 0.001 comparing groups as indicated in
the figure. See also Figures S1 and S2.exacerbation entailed a two-step process, whereby smoke
enhanced epithelial expression of IL-33 and virus-mediated
damage induced release, leading to an IL-33-dependent
amplification of anti-viral immunity. Importantly, smoke expo-
sure impaired the ability of the lung to mount a Th2 cell
response by suppressing ST2 expression and subsequent
IL-13 production in ILC2s, while simultaneously increasing
ST2 levels on NK cells and macrophages. This facilitated a
synergistic response to IL-33 in these cells, resulting in
elevated concentrations of proinflammatory cytokines such
as tumor necrosis factor-a (TNF-a), IL-12, and interferon-g
(IFN-g) and exaggerated Th1-like inflammation. Lastly, we
extended our findings to human COPD and show that elevated
epithelial IL-33 concentrations correlate with disease severity
and that viral infection induces significant IL-33 release from
human bronchial epithelial cells. This study provides insight
into how smoking might influence susceptibility to recurrent
infection in COPD and suggests that therapeutic intervention
of the IL-33 pathway might be of benefit in disease.RESULTS
IL-33 Is an Essential Trigger of COPD Exacerbations
in Mice
Prior smoke exposure in mice alters the response to viral infec-
tion (Bauer et al., 2010; Kang et al., 2008) and this has been
used as a model to investigate exacerbations in COPD. Because
IL-33 is found to be upregulated in COPD and plays a role in viral-
induced AHR (Byers et al., 2013; Kim et al., 2012), we examined
whether there was a role for IL-33 in a model of exacerbation.
Therefore, we exposed Il1rl1/ (encoding ST2; Townsend
et al., 2000), Il33/ (Figure S1A), or BALB/c mice to cigarette
smoke or room air and later infected them with influenza A virus
(Figure S1C; Bauer et al., 2010; Brown, 1990). In viral infection
alone (i.e., mice exposed to room air), we found that absence
of IL-33 or ST2 had minimal impact on the observed weight
loss and inflammatory response to infection (Figures 1A–1C,
data shown for Il1rl1/mice only). We next examined the exac-
erbation response and confirmed that prior smoke exposure inImmunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc. 567
BALB/c mice significantly enhanced weight loss to infection and
that this was associated with exaggerated lung inflammation, as
early as 2 days post infection (p.i.), when compared to viral
infection alone (Figures 1A–1C and S2A). Strikingly, IL-33 or
ST2 deficiency completely protected mice from these exacer-
bated responses (Figure 1). In addition, IL-33 or ST2 deficiency
resulted in a significantly diminished innate cell response in
macrophages, neutrophils, and NK cells, as well as T cells, at
2 and 6 days p.i. (Figures 1B and S2A). Interestingly, we
observed no impact on ILC expansion in Il1rl1/ animals during
the exacerbation phase (Figures S2B–S2D). IL-33 appeared to
be an early mediator in this exaggerated response because
absence of IL-33 signaling prevented enhanced secretion of
IFN-a, TNFa, IL-6, IL-12p40, and IFN-g as early as 2 days p.i.
(Figure 1C). Further, intervention with an ST2 fusion protein,
administered after virus infection, also protected mice from
exacerbated inflammation (Figure 1D). Importantly, protection
from exacerbated disease was not due to differences in viral
load (Figure 1E).
IL-33-Mediated COPD Exacerbations Require
a Two-Step Mechanism
Because prior smoke exposure was required to induce an IL-33-
dependent exacerbated inflammatory response to virus, we
questioned whether smoke could regulate IL-33 expression
and/or release. To this end, we exposedmice to acute or chronic
smoke (Figure S1D) and examined IL-33 expression. Immuno-
histochemical staining of mouse lung revealed constitutive
expression of IL-33 within alveolar type II (ATII) pneumocytes
(Figures 2A and 2B). Co-staining for IL-33 and pro-surfactant
protein C, (pSPC), a specificmarker for lung ATII cells, confirmed
that all ATII cells expressed IL-33 (Figure 2B). Surprisingly, just
4 days of smoke exposure markedly upregulated IL-33 expres-
sion within the lung, and this was further increased as smoke
was continued (Figures 2A–2C, quantified in 2D). Although ATII
cells remained the major IL-33-expressing cell, clear induction,
albeit more sparse, was also noted in the bronchial epithelium
(Figures 2C, S3A, and quantified in 2D). We observed a strong
correlation between increased IL-33 expression and numbers
of pSPC-expressing cells (Figure S3B). Mean intensity measure-
ments (data not shown) and cell counting confirmed that smoke
led to a significant increase in the numbers of IL-33+/pSPC+ ATII
cells within the lung rather than increased expression of IL-33 per
ATII cell (Figure S3C). Additional quantification of total protein in
lung homogenates confirmed that smoke exposure led to
elevated IL-33 expression, which was greatly increased over
time with smoke (Figure 2E). However, despite increased IL-33
expression after smoke exposure, blockade of this axis had no
significant impact on smoke-induced inflammation or emphy-
sema (Figures S3D–S3G). Thus, although smoke is a potent
regulator of IL-33 expression, this alarmin has no functional
role in smoke-induced pathologies.
The mechanisms underlying IL-33 release in vivo remain ill
defined but are presumed to mainly involve cell stress and/or
damage (Moussion et al., 2008), so we hypothesized that influ-
enza infection would induce epithelial damage and subsequent
IL-33 release. We were unable to detect IL-33 in BAL fluid and
therefore performed co-staining for both IL-33 and influenza A
virus. IL-33 expression was distributed uniformly throughout568 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.the lungs of smoke-exposed mice; however, after infection there
were large and patchy areas of lung for which IL-33 nuclear
expression was notably absent (Figure 2F). Detailed and exten-
sive quantification confirmed a strong spatial correlation be-
tween influenza-infected lung areas and a local reduction in
IL-33 staining; specifically, areas negative for influenza ex-
pressed profoundly more IL-33 than those where influenza was
present (Figure 2F and quantified in 2G). Furthermore, lactate de-
hydrogenase (LDH) activity in BAL fluid was highly increased in
virally infected mice compared with mock-infected or smoke-
exposedmice (Figure 2H). To directly assesswhether virus infec-
tion could induce IL-33 release, we cultured TC1 cells (mouse
epithelial cell line) and infected them with either influenza A or
RSV. Virus infection did indeed provoke release of IL-33 (Fig-
ure 2I) and, importantly, this correlated temporally with LDH
activity (Figure S3H). Thus, the mechanism for exacerbation is
two-fold: smoke is required to enhance epithelial IL-33, and
virus-mediated damage induces release.
Local IL-33 Reconstitution Is Sufficient to Exacerbate
the Immune Response to Infection
To test this two-step hypothesis, we postulated that exogenously
administered IL-33 would exaggerate virus-driven inflammation.
Indeed, a local bolus of recombinant IL-33 after virus infection
(Figure 3A) recapitulated many of the enhanced responses seen
after smoke and influenza A. We observed exaggerated weight
loss, increased inflammation (predominantly macrophages and
neutrophils), and amplified production of proinflammatory cyto-
kines, including TNF-a, IL-6, and IL-12p40. We also noted a
similar enhancement of CXCL5, consistent with increased neu-
trophilia in these mice (Figures 3B–3D). In the absence of smoke
exposure, we observed that IL-33 led to increases in IL-13; how-
ever, amounts were not further enhanced in the presence of
virus (Figure 3D). The exaggerated responses to IL-33 and virus
were absent in ST2-deficient animals, thereby suggesting that
increased local IL-33 concentrations, as observed after smoke
exposure, are sufficient to exacerbate a viral response.
Cigarette Smoke Suppresses IL-33-Induced Th2
Cytokine Production by ILC2s
IL-33 is a robust driver of Th2 cell responses, but paradoxically,
IL-33 release was not associated with an increased Th2 cell-like
signature in this COPD exacerbation model. Rather, the
observed inflammation resembled a Th1 cell proinflammatory
response (Figure 1C) and we did not detect IL-13 (Figure S2E).
Moreover, whereas viral infection increased the number of
ILCs in the lung, this was not further elevated by prior smoke
exposure (Figure S2D). To test whether smoke altered the lung’s
immune response to IL-33, mice were exposed to smoke or
room air and then intranasally challenged with IL-33 or PBS (Fig-
ure 4A). Without prior smoke exposure, we confirmed that IL-33
was a robust inducer of IL-13 and IL-5 production within the lung
(Figure 4B). However, when IL-33 was administered to smoke-
exposed mice, the production of these same cytokines was
markedly diminished (Figure 4B). The effects of smoke priming
were further investigated by performing a microarray on whole
lung tissue, and these data are visualized as a heatmap (Fig-
ure 4C). As previously shown (Botelho et al., 2011a; Qiu et al.,
2013), smoke exposure significantly induced IL-33, TNF-a,
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Figure 2. Smoke Exposure Drives Expression of IL-33 and Virus Infection Induces Release
Mice were exposed to cigarette smoke for 4 days, 8 weeks, or 16 weeks. 24 hr after the final exposure, lungs were sectioned and stained.
(A–C) Representative sections are shown for the lung parenchyma and bronchioles from smoke-exposed mice (ii) and their room air controls (i).
(A) Lung sections stained for IL-33 (green).
(B) Lung sections co-stained for IL-33 (green) and pro-surfactant C (pro-SPC; red) as a marker of ATII cells.
(C) IL-33 immunoreactivity (brown) in bronchioles from smoke-exposed mice (ii) but not room air controls (i).
(D) Staining was quantified as IL-33 positivity per total tissue area, and for the bronchial epithelium, the number of airways with IL-33 positivity.
(E) IL-33 concentrations were measured in lung tissue by ELISA.
Mice were exposed to cigarette smoke for 4 days, followed by influenza A infection on day 5 and analysis on day 11.
(F) Representative images showing patchy loss of IL-33 (green) in virus-infected (ii) but not control (i) mice.More detail is shown in (iii) and (iv) showing loss of IL-33
(blue) from influenza A (brown)-infected cells. White arrows show uninfected cells with nuclear IL-33 and black arrows show infected cells with less intense IL-33
staining.
(G) IL-33 release was quantified by co-staining for IL-33 (red) and influenza A (green) and assessing IL-33 intensity in influenza A, influenza A+, and influenza Ahi
squares of lung via a grid square analysis.
(H) Lactate dehydrogenase activity in BAL was quantified by colorimetric assay.
(I) TC1 cells were infected with influenza A or RSV or treated with Alternaria Alternata extract and assayed for IL-33 release by ELISA.
For (D), (E), (G), and (H), data are expressed asmean ± SEM, n = 8–16mice per group from 1–2 separate experiments, *p < 0.05, **p < 0.01 comparing smoke with
room air control. For (I), data are representative of three independent experiments. Scale bars represent 100 mm in (A), 10 mm in (Aii) inset, 40 mm in (B); 12 mm in
(Ci); and 10 mm a (Cii).
See also Figures S1 and S3.IL-1b, and MMP-12 mRNA in the lung. In contrast, smoke down-
regulated the constitutive levels of the Th2 cell-associated genes
Gata3, Il4ra, andPostn (encoding periostin) in the lung (Figure 4C,
top left). As expected, IL-33 induced a strong Th2 cell-like signa-
ture within the lungs of control mice (Figure 4C, right); however,
prior smoke exposure resulted in marked reductions in Gata3,Il13, Postn,Ccl11, and Il4ra, as well as the alternatively activated
macrophage genesCcl17,Ccl22, andChil3l (Figure 4C, right). To
identify which cells were being altered by smoke exposure, we
examined lung IL-5 and IL-13 production in lung T cells, NK cells,
and ILCs (gating shown in Figures S2 and S4) via flow cytometry
and stimulation of isolated cells. These studies revealed that theImmunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc. 569
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Figure 3. Local IL-33 Administration Enhances Viral Inflammation
(A) BALB/c and ST2-deficient mice were infected with virus, followed 8 hr later by intranasal IL-33.
(B) Body weights were measured throughout the experiment.
(C) Cell numbers were quantified in lung tissue by flow cytometry on day 6.
(D) Cytokine responses were measured in BAL supernatant by ELISA and MSD on day 2.
Data are expressed as mean ± SEM, n = 8 mice per group, **p < 0.01 comparing groups as indicated in the figure.smoke-induced changes were occurring predominantly within
the ILC2 population (Figures 4D, 4E, S4B, and S4C). Interest-
ingly, the suppressive effects of smoke on IL-5 and IL-13
production in ILC2s was sustained, as shown by the fact that
we were unable to override this effect when cells were re-chal-
lenged ex vivo with IL-2+IL-7 or PMA/ionomycin stimulation
(Figure S4D).
IL-33 Modulates Macrophage and NK Cell Function
to Enhance Th1 Cell-like Responses to Infection
Because smoke exposure appeared to silence ILC2 function, we
next investigated which cells were functionally responding to
IL-33 in our exacerbation model. ST2 is reportedly expressed
on a number of innate immune cells, including macrophages,
dendritic cells, NKT cells, and NK cells and, moreover, can func-
tionally amplify responses in some of these cells (Ohno et al.,
2011; Rank et al., 2009; Smithgall et al., 2008; Bartemes et al.,
2012). To address the mechanisms by which IL-33 was exacer-
bating disease, we attempted to identify the cellular sources of
proinflammatory cytokines significantly elevated after smoke
and virus. As demonstrated by intracellular staining, production
of TNF-a and IL-12p40 were markedly enhanced from macro-
phages and dendritic cells after smoke and virus. However,
these exaggerated cytokine levels were not observed in Il1rl1/
mice (Figure 5A). In addition, an ST2-dependent IFN-g produc-
tion was also localized to NK and CD8 T cells during the exacer-
bation phase; importantly, lack of IL-33 signaling had no impact570 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.on these cytokines during viral infection alone (Figure 5A). We
next investigated whether IL-33 could directly stimulate viral-
induced cytokine responses in macrophages in vitro. Interest-
ingly, BALB/c and Il1rl1/ bone-marrow-derived macrophages
responded similarly to the viral pathogen associated molecular
pattern (PAMP), poly(I:C), inducing robust increases in TNF-a
and IL-12p40 (Figure 5B). In contrast, suboptimal concentrations
of IL-33 had no impact on cytokine production; however, when
combined with poly(I:C), IL-33 induced a synergistic response
for TNF-a and IL-12p40; amplified responses were absent in
Il1rl1/ macrophages (Figure 5B).
NK cells reportedly express ST2 and are an important source
of IFN-g in response to virus infection. Given the diminished
IFN-g secretion in Il1rl1/ mice, we questioned whether IL-33
could modify IL-12-induced IFN-g production in NK cells iso-
lated from the spleens of BALB/c and Il1rl1/ mice. IL-33
evoked little response in NK cells, yet these cells produced sig-
nificant IFN-g (%1 ng/ml) in response to IL-12 (Figure 5C).
Remarkably, when combined, IL-33 and IL-12 had a synergistic
effect on IFN-g production (>15 ng/ml; Figure 5C).
Thus, in the presence of a suppressed Th2 cell-like response,
IL-33 can amplify cytokine production from macrophages and
dendritic cells, notably IL-12, leading to downstream effector
cell activation and exacerbated inflammation. To confirm our hy-
pothesis, we examined whether IL-12 could enhance the inflam-
matory response in vivo, specifically IFN-g production, observed
during viral infection. Therefore, BALB/c mice were infected with
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Figure 4. Smoke Alters the Lung’s Response to IL-33
(A) Mice were exposed to cigarette smoke or room air for 4 days and treated with intranasal IL-33 on days 3 and 4.
(B) Cytokine concentrations were quantified in the BAL supernatant by ELISA.
Data are expressed as mean ± SEM, n = 8 mice per group, **p < 0.01, ***p < 0.001 comparing groups as indicated in the figure.
(C) Microarray analysis was performed on whole lung mRNA. Data are visualized as a heatmap. Gene names with asterisk (*) denote statistical significance, with
the first column comparing room air and smoke and the second column comparing IL-33 and smoke+IL-33.
(D) ILCs were isolated from lung and assessed for IL-13 expression by flow cytometry. Representative FACS plots are shown.
(E) IL-13 and IL-5 concentrations were determined in the same isolated ILC supernatants after 24 hr of PMA/ionomycin stimulation by ELISA. Data are expressed
as mean ± SEM; n = 3–4 pooled samples per group, **p < 0.05 comparing the groups as indicated in the figure.
See also Figures S2 and S4.influenza A and/or intranasally treated with IL-12p70 or PBS
during infection (Figure S5A). IL-12 reconstitution markedly
enhanced the host response to infection; we observed signifi-
cant exaggerated weight loss and cellular inflammation in the
lungs of these mice compared to mice with viral infection alone
(Figures S5B–S5D). As expected, IL-12 significantly elevated
viral-induced IFN-g levels in BAL, as well as IL-6 and TNF-a (Fig-
ures S5E and S5F).
Smoke Alters the Lung’s Response to IL-33 by
Regulating Differential ST2 Expression
Because smoke altered responsiveness to IL-33 within the lung,
we questioned whether this was due to a differential expression
of ST2 on immune cells. To examine ST2 expression, we used an
antibody that has been widely cited (Schmitz et al., 2005; Neill
et al., 2010; Bartemes et al., 2012; Chang et al., 2011; Kim
et al., 2012; Townsend et al., 2000; Kearley et al., 2005). How-
ever, this antibody exhibited some non-specific binding, so
ST2 positivity was assessed by directly comparing with staining
on ST2-deficient cells. With this stringent gating, we determinedthat ILC2s were the predominant ST2+ cells within naive lung
(Figure S6). To investigate the effects of smoke, we first exam-
ined individual cellular ST2 levels via mRNA. Mice were exposed
to room air or smoke, the lungs were removed, and mRNA was
extracted from individual cell populations purified by cell sorting.
Surprisingly, we found that continuous smoke exposure induced
a dramatic loss of ST2 mRNA in ILC2s that was still evident after
10 days (Figure 6A). In contrast, ST2 mRNA levels were signifi-
cantly increased on NK cells, macrophages, and DCs (the latter
at day 10 only) when compared to the same cells from room-air-
exposed mice (Figure 6A). Interestingly, we found that mRNA
levels of IL-1 receptor accessory protein (IL-1RAcP), which is
required for ST2 signaling (Chackerian et al., 2007), significantly
tracked with loss or gain of ST2 expression on the same cells
(Figure 6A). To corroborate these changes, we examined ST2
expression via flow cytometry. Indeed, continuous smoke expo-
sure induced a dramatic time-dependent loss of ST2 cell surface
expression on ILC2s that was still evident after 5 weeks of smoke
(Figure 6B). In parallel, we observed a significant but simulta-
neous increase in ST2 levels on NK cells (after day 4) thatImmunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc. 571
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Figure 5. IL-33 Enhances Macrophage and NK Responses
BALB/c and ST2-deficient mice were exposed to cigarette smoke followed by infection with virus.
(A) On day 7, TNF-a and IL-12p40 production from lung tissue macrophages and dendritic cells, and IFN-g production from lung tissue NK and CD8 cells was
quantified by flow cytometry. Representative FACS plots are shown, alongside quantification.
(B) Bone-marrow-derived macrophages from BALB/c or ST2-deficient mice were stimulated with poly(I:C) in the presence or absence of IL-33, and cytokine
production was measured after 24 hr in supernatants by ELISA and MSD.
(C) NK cells were isolated from the spleens of BALB/c or ST2-deficient mice and stimulated with IL-33 in the presence of IL-12. IFN-g productionwasmeasured in
supernatants after 48 hr by MSD.
Data are expressed as mean ± SEM, n = 8 mice per group (A) or n = 3 separate cultures (B, C), *p < 0.05, **p < 0.01, ***p < 0.001 comparing groups as indicated in
the figure.remained elevated throughout chronic smoke exposure (Fig-
ure 6C). We were unable to confirm ST2 protein on DCs,
T cells, and macrophages because of low expression levels
and/or antibody sensitivity.
Lastly, we confirmed the loss or gain of ST2 functionality on
ILC2s and NK cells. ILC2s were purified from the lungs of room-
air- or smoke-exposed mice and stimulated with increasing con-
centrations of IL-33 to determine whether we could reverse the
suppressive effects of smoke. Smoke-exposed mice had mark-
edly reduced IL-5 and IL-13 production compared to room-air-
exposed mice at baseline and importantly, this suppression
was completely maintained after IL-33 stimulation (data shown
for IL-13 only, Figure 6D). Notably, the suppressive effect of572 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.smoke on ILC2 function was similar after acute or sub chronic
exposure (latter data not shown). To confirm that smoke led to
increased IL-33 responsiveness in lung NK cells, we purified
cells from the lungs of room-air- and smoke-exposed mice
and stimulated cells ex vivo with increasing concentrations of
IL-33 with or without a suboptimal dose of IL-12, and we deter-
mined IFN-g production. As previously demonstrated (Figure 5C),
IL-33 alone had no effect on IFN-g production in NK cells from
control mice, but in the presence of IL-12, IL-33 markedly
induced IFN-g production; interestingly, this synergy was
enhanced in NK cells from 4-day smoke-exposed mice (Fig-
ure 6E). Moreover, when we examined NK cells after 10 days
of smoke, IL-33 alone was now able to induce a significant
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Figure 6. Smoke Alters Patterns of ST2 Expression in the Lung
Mice were exposed to cigarette smoke as indicated in the figure.
(A) Lung cell subsets were isolated by flow cytometric sorting and assessed for ST2 and IL-1RAcP mRNA expression by Taqman. Data are expressed as fold
change above room air controls, n = 10–15 mice per group.
(B and C) ST2 protein expression was determined in ILCs (B) and NK cells (C) by flow cytometry. Representative FACS plots are shown and data were quantified
as mean fluorescence intensity (MFI). Data are expressed mean ± SEM, n = 3–10 mice per group.
(D) ILCs were isolated from lung and stimulated with varying amounts of IL-33 for 24 hr.
(E) Isolated lung NK cells were cultured for 48 hr in the presence of varying amounts of IL-33 with or without IL-12. Data shown are representative of two in-
dependent experiments for both cell types pooled from 10–15 mice.
See also Figure S6.dose-related increase in IFN-g production (%7.5 ng/ml), and
these levels were dramatically exaggerated (R17.5 ng/ml) in
the presence of IL-12 (Figure 6E). Collectively, these data
confirm the differential expression of ST2 on ILC2s and NK cells
in the lung after continuous smoke exposure. Thus, smoke im-
pairs the ability of the lung to mount a Th2 cell response via
decreasing ILC responsiveness to IL-33 and concomitantly by
inducing NK cells to respond directly to this cytokine.
IL-33 Correlates with Disease Severity in COPD and Is
Released in Response to Infection
To extend our observations to human disease, IL-33 immunore-
activity was examined in lung sections from controls, smokers,
and COPD patients (Table S1). As previously described for the
lung (Moussion et al., 2008; Pre´fontaine et al., 2009, 2010),IL-33 was constitutively expressed in the nucleus of structural
cells, foremost in epithelial and endothelial cells but also in fibro-
blasts and smooth muscle (Figure 7A). In COPD, the total lung
expression was markedly increased for IL-33, with the most
striking upregulation being observed in the airway epithelium
(Figure 7A and quantified in 7B). Epithelial staining was largely
restricted to basal cells, although we also noted some positive
staining within columnar epithelial cells. This was much more
pronounced in severe COPD (Figure 7A, iii–v). Indeed, IL-33
expression correlated well with disease severity, with the highest
levels being observed in GOLD IV patients (Figure 7B). Strikingly,
there was a pronounced negative correlation between IL-33
levels and lung function as assessed by FEV1% predicted and
FEV1/FVC ratio (Figures 7C and S7A). In a different patient
cohort (Table S2), we found that the levels of IL-33 protein inImmunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc. 573
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Figure 7. IL-33 Expression Is Increased in Severe COPD
Lung biopsies from COPD patients (GOLD I-IV), smokers, and healthy controls (never smokers) were sectioned and stained for IL-33.
(A) Representative sections are shown from healthy controls (i–ii) and GOLD IV (iii–v). Scale bars represent 180 mm (i, iii), 60 mm (ii, iv), or 8 mm (v).
(B) Staining was quantified by as IL-33 positivity per total tissue area, and for the bronchial epithelium, the number of airways with IL-33 positivity.
(C) Correlative analysis between IL-33 staining and lung function as measured by FEV1 (percent predicted) was performed for all subjects.
(D) In a separate study, IL-33 concentrations were measured in lung tissue homogenate by bead-based immunoassay.
(E) Primary human bronchial epithelial cells were infected with influenza A, RSV, or rhinovirus or treated with Alternaria Alternata extract. IL-33 was measured in
the supernatant 1–72 hr after infection by ELISA.
Data are expressed as median (B and D) or are representative of two independent experiments (E). *p < 0.05, ***p < 0.001 comparing groups as indicated in the
figure. See also Figure S7 and Tables S1 and S2.lung homogenates were significantly increased in patients with
severe COPD compared with healthy controls (Figure 7D).
We next examined whether viral infection would trigger IL-33
release in human epithelial cells. Infection with rhinovirus, RSV,
or influenza, the prevalent viruses associated with exacerbations
(Mohan et al., 2010), induced significant IL-33 release from pri-
mary bronchial epithelial cells (Figure 7E) and A549 cells (Fig-
ure S7B). Similar to our observations in mice, the amount of IL-
33 consistently correlated with significant LDH activity, suggest-
ing that cellular damage was required for release (Figures S7B
and S7C). In contrast,Alternaria Alternata extract, a positive con-
trol for active IL-33 release (Kouzaki et al., 2011), induced signif-
icant IL-33 secretion within 1 hr in the absence of significant LDH
activity (Figures 7E, S7B, and S7C).
DISCUSSION
In this report, we describe a novel role for the IL-33/ST2 axis in
smoke-induced exacerbations that are associated with COPD.574 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.Specifically, we demonstrate that smoke exposure primes the
lung by significantly increasing intracellular epithelial expression
of IL-33, which is released locally upon virus infection and exac-
erbates disease. In addition, smoke alters the ST2 expression
pattern in the lung, impairing its ability to mount a Th2 cell
response, thereby facilitating an alternative pathway for IL-33
that markedly exaggerates the inflammatory response to infec-
tion. Our data shift the paradigm of IL-33 as a driver of Th2 cell
responses by clearly demonstrating that IL-33 can also poten-
tiate classical virus-induced inflammation.
One of the key characteristics of COPD is debilitating exacer-
bations of disease, typically induced by viral and/or bacterial
infections (Sethi and Murphy, 2008). Although exaggerated in-
flammatory responses are probably driving episodes of acute
exacerbations, the mechanisms underlying these disease-modi-
fying events remain unknown (Mallia et al., 2011). Here we pro-
pose that the IL-33/ST2 pathway is a central mechanism by
which exaggerated responses to pathogens occur in COPD pa-
tients. First, we demonstrate that cigarette smoke is a potent
regulator of IL-33 expression, specifically increasing intracellular
IL-33 concentrations within the airway epithelium. Of interest is
our observation that smoke led to a significant increase in the
numbers of IL-33+/pSPC+ ATII cells, providing a mechanism by
which IL-33 expression is elevated with smoke. Notably, smoke
is not an active inducer of IL-33 release because expression re-
mained strongly nuclear even during chronic exposure, although
it is probable that undetectable amounts of this cytokine are
passively released over time. Moreover, absence of IL-33 or
ST2 conferred no significant protection from smoke-induced
inflammation or emphysema, nor did impairing IL-33 signaling
with an ST2 fusion protein have any impact on responses to
smoke. Collectively, these data demonstrate that smoke is a
potent regulator of IL-33 expression but is not required for
smoke-induced injury. These findings are at odds with a recent
report demonstrating that a polyclonal anti-IL-33 antibody
partially reduced acute smoke-driven inflammation (Qiu et al.,
2013) but are consistent with a non-redundant role for the
IL-1R1/IL-1a axis in smoke-induced inflammation (Botelho
et al., 2011a; Pauwels et al., 2011).
In contrast to smoke, inoculationwith influenza A resulted in an
unevenly distributed loss of nuclear IL-33, suggestive of release.
This was probably due to virus-induced cell damage, in that it
correlated with presence of virus and a dramatic increase in
LDH activity. Indeed, by usingmouse and primary human epithe-
lial cell cultures, we showed that virus infection induced IL-33
elaboration at time points correlating with LDH activity. Impor-
tantly, IL-33 release from human epithelium was not specific to
influenza but also associated with rhinovirus and RSV infection,
notably viruses shown to be highly prevalent in COPD (Sethi and
Murphy, 2008;Mohan et al., 2010; De Serres et al., 2009). Collec-
tively, these data highlight the importance of epithelial-derived
IL-33 during disease and thus corroborate the involvement of
this cytokine in virally triggered exacerbations of COPD.
It is noteworthy that IL-33 or ST2 deficiency had no significant
impact on the inflammatory effects induced by influenza infec-
tion alone. Instead, IL-33 was required for the exacerbated
inflammation seen when mice were infected after smoke expo-
sure. ST2-deficient mice have previously been shown to be pro-
tected from AHR, a phenomenon characteristic of asthma
(Chang et al., 2011). Interestingly, AHR was induced after influ-
enza infection but was paradoxically shown to involve macro-
phage-derived IL-33 that enhanced ILC2 production of IL-13
(Chang et al., 2011). However, in our model, we observed no
Th2 or IL-13 signature in the lungs of mice exposed to smoke
and virus. Further, we demonstrate that themajor IL-33-express-
ing cell type in themouse lung after smoke was the epithelial cell,
and moreover showed that this was also the case in COPD lung.
The kinetics of virus-induced IL-33 release was consistent
with the exaggerated ST2-dependent inflammatory responses
observed at 2 days p.i. (i.e., during the exacerbation phase).
Therefore, extracellular IL-33 concentrations increase early dur-
ing infection and are thus likely to act on local innate immune
cells present in the lung. The recent discovery of lung ILCs that
are responsive to IL-33 (Monticelli et al., 2011) led us to investi-
gate whether these could be responsible for the exacerbated
inflammation. However, although we confirmed a small, ST2-
dependent increase in ILCs in response to virus alone (Kim
et al., 2012), numbers were not further increased by ST2 defi-ciency in the presence of smoke and virus. Notably, ST2 is highly
expressed on ILC2s (Moro et al., 2010; Monticelli et al., 2011),
which, at baseline, appear to be the only significant ST2+ cells
within the lung (Halim et al., 2012), constituting approximately
85% of the total lung ILC population. IL-33 has been shown to
mediate ILC2 expansion and immune responses via secretion
of IL-5 and IL-13 (Neill et al., 2010; Moro et al., 2010; Price
et al., 2010; Mjo¨sberg et al., 2011), cytokines that were not de-
tected in this exacerbation model. Indeed, in the absence of
smoke, IL-33 was a potent inducer of IL-5 and IL-13 production
in ILC2s but not in T cells or NK cells present in the lung at the
same time. Smoke markedly silenced the production of IL-5
and IL-13 in ILC2s; remarkably, this was associated with a dra-
matic and concomitant loss of ST2 and IL-1RAcP expression
that was further reduced with continuous smoke exposure.
Moreover, our gene array confirmed a general suppression of
Th2-cell-like responses in the lung, including the key Th2-cell-
associated factors GATA3, IL-4Ra, periostin, IL-13, and
CCL11, as well as IL-33-induced molecules associated with
M2 polarization such as CCL17, CCL22, and Chil3l (Kurowska-
Stolarska et al., 2009). We report that smoke exposure silences
ILC2 function in the lung and, as such, provides insight into the
mechanisms underlying earlier reports of cigarette smoke sup-
pressing allergen-induced responses (Botelho et al., 2011b).
Specifically, the simultaneous reduction in GATA3 lung tran-
script and the dramatic loss of ST2 and IL-1RAcP expression
on ILC2s provides an explanation as to how smoke prevents
the default pathway for IL-33 in the lung, i.e., activation of a func-
tional ILC2 response (Bartemes et al., 2012), and is supported by
a recent study linking GATA3 regulation with expression of Th2-
cell-related molecules including ST2, IL-5, IL-13, and amphire-
gulin in these cells (Yagi et al., 2014). Thus, in the absence of a
functional ILC2 response, an alternative pathway is facilitated
whereby IL-33 activates other ST2-expressing cells in the lung
to promote a Th1 cell proinflammatory response to infection.
In addition to ILC2s being the primary ST2+ cells in naive lung,
macrophages and dendritic cells have also been shown to ex-
press this receptor (Ohno et al., 2011; Rank et al., 2009), and
we observed an early IL-33-dependent increase in both macro-
phage- and dendritic-cell-derived TNF-a and IL-12p40 in vivo.
Therefore, we hypothesized that IL-33 might contribute to
increased inflammation by amplifying macrophage function.
Consistent with this hypothesis, we found that smoke directly
unregulated ST2 and IL-1RAcP mRNA expression on these cells
and importantly demonstrated that IL-33 can markedly poten-
tiate macrophage responses to the viral PAMP, poly(I:C). This
observation expands a previous report demonstrating that
IL-33 can augment macrophage responses to LPS (Ohno
et al., 2011).
NK cells have been shown to express ST2 in response to IL-12
(Smithgall et al., 2008), which is produced by activated macro-
phages, monocytes, and dendritic cells and promotes IFN-g
production byNK cells and T cells (Monteiro et al., 1998). Indeed,
we found that ST2-deficient mice had significantly less virus-
induced IFN-g production from NK cells compared with controls
and, in vitro, these cells failed to produce IFN-g in response to
IL-33 or poly(I:C). Instead, when stimulated with IL-12 in the
presence of IL-33, there was a remarkable synergistic effect on
IFN-g release, corroborating a role for IL-12 in upregulatingImmunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc. 575
ST2 expression on NK cells (Smithgall et al., 2008). Further, our
observation of increased IL-12p40 secretion upon infection with
smoke could explain the enhanced IFN-g production from NK
cells. In addition, we demonstrate that smoke exposure directly
upregulates ST2 and IL-1RAcP expression on lung NK cells.
These data were supported by functional studies showing that
NK cells from the lungs of smoke-exposed mice no longer
require endogenous IL-12 in order to respond to IL-33. Interest-
ingly, we found no evidence of enhanced viral titers in the
absence of IL-33 aswas previously suggested during LCMV sys-
temic infection, although this was limited to a small number of
activated ST2+ CD8 T cells and high-dose infection (Bonilla
et al., 2012). Together, these findings support our hypothesis
that after smoke exposure and virus infection, IL-33 can amplify
cytokine production frommacrophages and dendritic cells, spe-
cifically IL-12, leading to increased NK-cell-exacerbated inflam-
mation. Thus, macrophages and NK cells might play a critical
role during viral exacerbations. However, significant effects after
macrophage or NK cell depletion (data not shown) and reports of
IL-12 blockade/deficiency during pulmonary viral infection alone
(Monteiro et al., 1998; Wang et al., 2004; Chakraborty et al.,
2012) precluded us from deciphering the contribution of this
pathway during exacerbation (i.e., smoke and virus). Importantly,
local reconstitution of IL-12p70 during an influenza infection
recapitulated many of the features seen in our exacerbation
model and validated the central role of this cytokine in enhancing
the host response to infection.
Of relevance, we substantiate our findings in mice by confirm-
ing a significant upregulation of IL-33 expression in human
COPD. Remarkably, the IL-33 expression patterns observed in
mice were similar to that seen in COPD, in that protein amounts
within the airway epithelium are specifically regulated via smoke
and/or disease. Notably, protein concentrations of this cytokine
were markedly increased in severe patients and inversely corre-
lated with lung function decline. Our data from two separate
COPD patient cohorts confirm and expand a previous observa-
tion in COPD (Byers et al., 2013) by demonstrating that increased
expression of IL-33 correlates with progression of severe dis-
ease. Moreover, the notion that viruses associated with COPD
trigger epithelial-derived IL-33 release provides further evidence
that this cytokine contributes to exacerbations of disease.
The mechanisms underlying the exaggerated responses
induced by pathogens in COPD are thought to be associated
with an inappropriate host response (Mallia et al., 2011). Here
we provide evidence that the IL-33/ST2 axis is central to this
exaggerated response. Indeed, treatmentwith an ST2 fusion pro-
tein during infection was sufficient to offset exacerbation in this
mouse model, and, conversely, local IL-33 administration prior
to infection recapitulated the exaggerated response. It is note-
worthy that cigarette smoke exposure altered the cell-intrinsic
expression of ST2 within the lung, silencing the function of
ILC2s and promoting an altered responsiveness of IL-33 via the
innate anti-viral effectors, namely macrophages and NK cells,
the consequence of which shifted toward an enhanced Th1 cyto-
kine response to infection. Indeed, current literature supports the
notion that IL-33 can function as a pleiotropic cytokine mediating
both Th2 and Th17 cell responses (Palmer and Gabay, 2011; Xu
et al., 2008; Cho et al., 2012). Here we provide evidence that the
IL-33/ST2 axis can also significantly influence Th1-like viral re-576 Immunity 42, 566–579, March 17, 2015 ª2015 Elsevier Inc.sponses. Our observations are in keeping with a role for IL-33
driving IFN-g production from NK TNKT, NK, and CD8 T cells
(Smithgall et al., 2008; Bourgeois et al., 2009; Yang et al., 2011;
Bonilla et al., 2012) and moreover complement a recent report
for this alarmin in anti-tumor immunity, whereby IL-33 was shown
to enhance Th1 and CD8 T cell antigen-specific responses and
provide a protective antiviral CTL response in a tumor setting (Vil-
larreal et al., 2014). Thus, it is tempting to speculate that IL-33
might function as a global amplifier of immune responses, rather
than as a mediator that skews the ensuing immune pathology to-
ward a specific T helper cell phenotype. Further, therapeutic
impact on this pathway could lead to a reduction in exacerbation
rates and ultimately prevent progression of COPD.
EXPERIMENTAL PROCEDURES
COPD Cohorts
Two separate and independent patient cohorts were used for assessment of
IL-33 expression in COPD. More details of each cohort are provided in the
Supplemental Experimental Procedures and Tables S1 and S2.
Culture and Stimulation of TC1, A549, and Primary Bronchial
Epithelial Cells
IL-33 release was measured in response to Alternaria Alternata, influenza A,
RSV, and HRV (human cells only) in TC1 (mouse), A539 (human), and normal
human bronchial epithelial cells. More details are given in the Supplemental
Experimental Procedures.
Mice
BALB/c female mice were from Harlan. ST2-deficient mice were generated as
previously described (Townsend et al., 2000). IL-33-deficient micewere gener-
ated in collaboration with TaconicArtemis (Figure S1 and Supplemental Exper-
imental Procedures). Both ST2-deficient and IL-33-deficient mice were on a
BALB/c background. All studies were performed under protocols approved
by MedImmune’s Institutional Animal Care and Use Committee.
Induction of Smoke-Induced Inflammation and Viral Exacerbation
Micewere exposed to cigarette smoke via a whole-body smoke exposure sys-
tem (SIU-48, Promech Lab AB), then infected with influenza A as previously
described (Bauer et al., 2010). In some experiments, mice were treated with
ST2-Fc (R&D; 10 mg/kg daily i.p.). Dosing took place during the virus infection
phase (days 5–10). In other experiments, instead of smoke, mice received 5 mg
IL-33 intranasally 8 hr after virus infection (Figure 3A). In further experiments,
mice received 250 ng IL-12 intranasally given 8 hr after virus and on days
1–3 (Figure S5A).
Induction of Acute and Chronic Smoke-Induced Inflammation
Mice were exposed to cigarette smoke twice daily for 4 days (acute smoke) or
5 days/week for 8 and 16 weeks (chronic smoke; Figure S1D). In some acute
smoke experiments, mice were treated with ST2-Fc (R&D; 10 mg/kg daily i.p.,
days 1–4). For chronic models, emphysema was quantified by lung function
measurements (FlexiVent) as previously described (Vanoirbeek et al., 2010).
Effect of Smoke Priming on IL-33 Responses
Mice were exposed to cigarette smoke on days 1–4 and treated with intranasal
IL-33 (5 mg) on days 3–4. Analysis was performed on day 5. A schematic is
shown in Figure 4A.
Quantification of Lung Inflammation
BAL and lung tissue digest followed by differential counting were performed as
previously described (Kearley et al., 2005).
Measurement of mRNA and Cytokine Release from Lung Cell
Subsets
Lungs were digested as previously described (Kearley et al., 2005). For
enrichment of ILCs, cells were incubated with Biotin Mouse Lineage Panel
(BD) followed by biotin microbeads and magnetic depletion according to
manufacturer’s protocol (Miltenyi). T cells and NK cells were enriched by
magnetic separation according to the manufacturer’s protocol (Miltenyi).
For mRNA analysis of individual cell types, cells were stained (see Flow
Cytometry Analysis) and sorted with a FACSAria (BD) with the exception
of ILCs that were sorted as above. Populations were defined as
follows: T cells (CD3+), NK cells (CD49b+), Macs (CD11b+F4/80+), DCs
(CD11C+MHCII+).
For cytokine analysis, each population was incubated with PMA and iono-
mycin (Life Technologies). After 24 hr, cells were incubated for 4 hr with
Brefeldin A (Biolegend) before being surface stained, fixed, and stained for
intracellular cytokines. Supernatants were assayed for cytokines by ELISA
or MSD.
To assess NK cell and ILC function after smoke, lung NK cells and ILCs were
sorted as above. Cells were incubated with varying amounts of IL-33 with IL-12
(NK cells) for the times stated in the figure legend. Cytokine productionwas as-
sessed in supernatant by ELISA or MSD.
Generation of Bone-Marrow-Derived Macrophages
Bone marrow was harvested from the femurs and tibia of BALB/c or ST2-defi-
cient mice and cultured for 7 days in the presence of M-CSF (25 ng/ml; Pepro-
tech). Macrophages were stimulated with combinations of IL-33 (10 ng/ml;
Axxora) and poly(I:C) (10 mg/ml; Invivogen) for 24 hr, after which supernatants
were assayed for cytokines.
NK Cell Isolation from Spleen
NK cells were isolated from the spleens of BALB/c or ST2-deficient mice with
an NK cell isolation kit according to the manufacturer’s protocol (Miltenyi). NK
cells were stimulated with IL-33 (10 ng/ml) and/or IL-12 (10 ng/ml; Biolegend)
for 48 hr, after which supernatants were assayed for IFN-g.
Flow Cytometric Analysis
Flow cytometry was performed on lung tissue digest cells as previously
described (Kearley et al., 2005). Antibodies against CD4, CD8, CD11b,
CD49b, TCRb, MHCII, IL-4, and Gr-1 (BD), F4/80, IL-7Ra, ICOS, CD11c,
CD5, CD27, CD19, IL-13, IFN-g, and IL-12p40 (eBioscience), and B220,
TCR gd, CD45, CD90, and TNF-a (Biolegend) were all used.
Quantification of Cytokines
IFN-g, TNF-a, and IL-6 were quantified in BAL supernatant by multiplex anal-
ysis according to the manufacturer’s protocol (MesoScale Discovery). IFN-a,
IL-12p40, CXCL5, IL-13, IL-5, andmouse and human IL-33 were quantified ac-
cording to the manufacturer’s protocol (R&D). Human IL-33 was quantified in
lung tissue homogenates in cohort 2 via a bead-based immunoassay (Milliplex,
Millipore) according to the manufacturer’s protocol. Results were normalized
to lung homogenate total protein concentration determined with the BCA pro-
tein assay (Pierce).
Quantification of Lactate Dehydrogenase
LDHwasmeasured in BAL or tissue culture supernatant according to theman-
ufacturer’s protocol (Promega). Data were expressed as absorbance at
450 nm or in arbitrary units via a standard curve made with serial dilutions of
the provided LDH-positive control.
Immunohistochemical Staining of Mouse and Human Lung
Paraffin sections from human lung were stained for IL-33. Paraffin sections
from mouse lung were stained for IL-33, influenza A, and Pro-SPC, alone
and in combinations. More details are provided in the Supplemental Experi-
mental Procedures.
Statistics
Statistical analyses were performed as described in each figure legend via
GraphPad Prism.
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